{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:40:15Z","timestamp":1761856815087,"version":"build-2065373602"},"reference-count":12,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","pathologyjournal.rcpa.edu.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.pathol.2020.08.017","type":"journal-article","created":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T09:54:36Z","timestamp":1605779676000},"page":"675-678","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pembrolizumab associated sarcoid-like lymphadenopathy mimicking progressive disease in Hodgkin lymphoma"],"prefix":"10.1016","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7376-4621","authenticated-orcid":false,"given":"Bruce Tsz Chun","family":"Chau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Penelope","family":"McKelvie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6566-6215","authenticated-orcid":false,"given":"Ali","family":"Bazargan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhajir","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pathol.2020.08.017_bib1","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pathol.2020.08.017_bib2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood.2019000215","article-title":"PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation","volume":"134","author":"Armand","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2020.08.017_bib3","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40425-018-0323-0","article-title":"Granulomatous\/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients","volume":"6","author":"Tetzlaff","year":"2018","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.pathol.2020.08.017_bib4","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jdcr.2016.06.004","article-title":"Pembrolizumab-associated sarcoidosis","volume":"2","author":"Cotliar","year":"2016","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.pathol.2020.08.017_bib5","doi-asserted-by":"crossref","first-page":"755","DOI":"10.6004\/jnccn.2020.0026","article-title":"Hodgkin lymphoma. NCCN clinical practice guidelines in oncology","volume":"18","author":"Hoppe","year":"2020","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.pathol.2020.08.017_bib6","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4137\/CCRep.S5243","article-title":"Sarcoid reactions after chemotherapy for Hodgkin\u2019s lymphoma","volume":"3","author":"Wirk","year":"2010","journal-title":"Clin Med Insights Case Rep"},{"key":"10.1016\/j.pathol.2020.08.017_bib7","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1186\/1752-1947-5-247","article-title":"18F-fluorodeoxyglucose positron emission tomography-positive sarcoidosis after chemoradiotherapy of Hodgkin\u2019s disease: a case report","volume":"5","author":"Cherk","year":"2011","journal-title":"J\u00a0Med Case Rep"},{"key":"10.1016\/j.pathol.2020.08.017_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MD.0000000000000121","article-title":"Sarcoidosis occuring after lymphoma","volume":"93","author":"London","year":"2014","journal-title":"Medicine"},{"key":"10.1016\/j.pathol.2020.08.017_bib9","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ejca.2020.02.024","article-title":"Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: increased rate and mimicker of metastasis","volume":"131","author":"Chorti","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.pathol.2020.08.017_bib10","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/ejh.12770","article-title":"Pembrolizumab in classical Hodgkin\u2019s lymphoma","volume":"97","author":"Maly","year":"2016","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.pathol.2020.08.017_bib11","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/cup.13569","article-title":"Granulomatous\/sarcoid-like reactions in the setting of programmed cell death-1 inhibition: a potential mimic of disease recurrence","volume":"47","author":"Hiraki","year":"2020","journal-title":"J\u00a0Cutan Pathol"},{"key":"10.1016\/j.pathol.2020.08.017_bib12","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1080\/1744666X.2016.1181541","article-title":"Advances in understanding the immunopathology of sarcoidosis and implications on therapy","volume":"12","author":"Cinetto","year":"2016","journal-title":"Expert Rev Clin Immunol"}],"container-title":["Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302520309594?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302520309594?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T16:27:39Z","timestamp":1758472059000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031302520309594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":12,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S0031302520309594"],"URL":"https:\/\/doi.org\/10.1016\/j.pathol.2020.08.017","relation":{},"ISSN":["0031-3025"],"issn-type":[{"type":"print","value":"0031-3025"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pembrolizumab associated sarcoid-like lymphadenopathy mimicking progressive disease in Hodgkin lymphoma","name":"articletitle","label":"Article Title"},{"value":"Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pathol.2020.08.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}